Tularemi: Güncel tedavi seçeneklerine genel bir bakış
Yıl: 2011 Cilt: 24 Sayı: 1 Sayfa Aralığı: 2 - 10 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Tularemi: Güncel tedavi seçeneklerine genel bir bakış
Öz: Tularemi, Francisella tularensisin etken olduğu, dünya çapında bir dağılım gösteren ve farklı klinik belirtilerle seyreden zoonotik bir infeksiyon hastalığıdır. İnsanlarda klinik tablo lokalize hastalıktan fülminan, yaşamı tehdit eden pnömoni veya septisemiye kadar değişmektedir. Tularemi tedavisinde yıllardır streptomisin, gentamisin ve tetrasiklin kullanılmaktadır, ancak son zamanlarda kinolonlar önemli bir alternatif olarak kabul edilmektedir. Buna rağmen tularemi tedavisinde antibiyotiklerin etkinliklerini karşılaştıran randomize kontrollü çalışmalar bulunmamaktadır. Son yıllarda ülkemizde tulareminin endemik olduğu bölgeler dışında görülen salgınlarındaki artış bu hastalığa karşı ilgiyi artırmıştır. Bu derlemede, tularemi tedavisi hakkındaki öneriler güncel literatür ışığında sunulmuştur.
Anahtar Kelime: Konular:
Tularemia: A general overview on current treatment options
Öz: Tularemia is a zoonotic infection caused by Francisella tularensis with a worldwide distribution and diverse clinical manifestations. In humans, the disease varies from a localized illness to fulminant, life-threatening pneumonia or septicemia. For decades, streptomycin, gentamicin, and tetracycline have been used for the treatment of tularemia, but more recently, quinolones have been considered as acceptable alternatives. However, there are no randomized trials supporting the use of these antibiotics compared with each other. The increasing number of tularemia outbreaks in regions of Turkey outside the classic endemic areas in recent years has prompted renewed interest in this infectious disease. In this review, suggestions about treatment of tularemia are presented in the light of current literature.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1.Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002; 15(4): 631-46. [Crossref]
- 2.WHO Guidelines on Tularaemia [İnternet]. Geneva: World Health Organization [erişim 2 Mart 2011]. http://www.who.int/csr/resources/publications/WHO_CDS_EPR_2007_7.pdf.
- 3.Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007; 1105: 1-29.
- 4.Penn RL. Francisella tularensis (tularemia). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennetts Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005: 2674-85.
- 5.Kılıç S. Francisella tularensis ve Türkiyede tularemi epidemiyolojisine genel bir bakış. Flora. 2010; 15(2): 37-58.
- 6.Tärnvik A, Berglund L. Tularemia. Eur Respir J. 2003; 21(2): 361-73. [Crossref]
- 7.Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci. 2007; 1105: 378-404.
- 8.Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther. 2008; 6(2): 231-40. [Crossref]
- 9.Ericsson M, Sandström G, Sjöstedt A, Tärnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to th intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis. 1994; 170(1): 110-4. [Crossref]
- 10.Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30- year experience with 88 cases. Medicine (Baltimore). 1985; 64(4): 251-69. [Crossref]
- 11.Centers for Diseases Control (CDC). Tularemic pneumonia Tennessee. MMWR Morb Mortal Wkly Rep. 1983; 32(20): 262-4.
- 12.Provenza JM, Klotz SA, Penn RL. Isolation of Francisella tularensis from blood. J Clin Microbiol. 1986; 24(3): 453-5.
- 13.Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol. 2009; 66(4): 523-7. [Crossref]
- 14.Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch Intern Med. 1987; 147(2): 265-8. [Crossref]
- 15.Christenson B. An outbreak of tularemia in the northern part of central Sweden. Scand J Infect Dis. 1984; 16(3): 285-90. [Crossref]
- 16.Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, Mena- Martín FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis. 2001; 33(4): 573-6. [Crossref]
- 17.Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994; 19(1): 42-7. [Crossref]
- 18.Dennis DT. Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA.2001; 285(21): 2763-73. [Crossref]
- 19.Maurin M, Mersali NF, Raoult D. Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother. 2000; 44(12): 3428-31. [Crossref]
- 20.Foshay L, Pasternack AB. Streptomycin treatment of tularemia. J Am Med Assoc. 1946; 130: 393-8. [Crossref]
- 21.Mason WL, Eigelsbach HT, Little SF, Bates JH. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis. 1980; 121(1): 39-45.
- 22.Cross JT Jr, Schutze GE, Jacobs RF. Treatment of tularemia with gentamicin in pediatric patients. Pediatr Infect Dis J. 1995; 14(2): 151-2.
- 23.Hassoun A, Spera R, Dunkel J. Tularemia and once-daily gentamicin. Antimicrob Agents Chemother. 2006; 50(2): 824. [Crossref]
- 24.Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother. 2000; 46(2): 287-90.
- 25.Tomaso H, Al Dahouk S, Hofer E, et al. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents. 2005; 26(4): 279-84. [Crossref]
- 26.García del Blanco N, Gutiérrez Martín CB, de la Puente Redondo VA, Rodríguez Ferri EF. In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents. Res Vet Sci. 2004; 76(3): 195-8. [Crossref]
- 27.Scheel O, Hoel T. Sandvik T, Berdal BP. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS. 1993; 101(1): 33-6. [Crossref]
- 28.Jounio U, Renko M, Uhari M. An outbreak of holarctica-type tularemia in pediatric patients. Pediatr Infect Dis J. 2010; 29(2): 160-2 [Crossref].
- 29.Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev.1966; 30(3): 542-50.
- 30.Syrjälä H, Herva E, Ilonen J, Saukkonen K, Salminen A. A whole- blood lymphocyte stimulation test for the diagnosis of human tularemia. J Infect Dis. 1984; 150(6): 912-5.
- 31.Tärnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis. 1989; 11(3): 440-51.
- 32.Overholt EL, Tigertt WD, Kadull PJ, et al. An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am J Med. 1961; 30: 785-806. [Crossref]
- 33.Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother. 1977; 11(3): 462-9. [Crossref]
- 34.Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother. 2008; 52(6): 2276-8. [Crossref]
- 35.Johansson A, Urich SK, Chu MC, Sjöstedt A, Tärnvik A. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis. 2002; 34(5): 327-30. [Crossref]
- 36.Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J Antimicrob Chemother.1998; 41(4): 461-5. [Crossref]
- 37.Syrjälä H, Schildt R, Räisäinen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991; 10(2): 68-70. [Crossref]
- 38.Scheel O, Reiersen R, Hoel T. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1992; 11(5): 447-8. [Crossref]
- 39.Johansson A, Berglund L, Sjöstedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia. Clin Infect Dis. 2001; 33(2): 267-8. [Crossref]
- 40.Meric M, Willke A, Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS. 2008; 116(1): 66-73. [Crossref]
- 41.Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis. 2000; 31(2): 623. [Crossref]
- 42.Uhari M, Syrjälä H, Salminen A. Tularemia in children caused by Francisella tularensis biovar palaearctica. Pediatr Infect Dis J.1990; 9(2): 80-3. [Crossref]
- 43.Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J. 2000; 19(5): 449-53. [Crossref]
- 44.Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995; 14(1): 1-9. [Crossref]
- 45.Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis. 1999; 29(4): 922-4. [Crossref]
- 46.Aranda EA. Treatment of tularemia with levofloxacin. Clin Microbiol Infect. 2001; 7(3): 167-8. [Crossref]
- 47.Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis. 1993; 17(6); 976-80. [Crossref]
- 48.Harrell RE Jr, Simmons HF. Pleuropulmonary tularemia: successful treatment with erythromycin. South Med J. 1990; 83(11): 1363-4. [Crossref]
- 49.Kudelina RI, Olsufiev NG. Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. J Hyg Epidemiol Microbiol Immunol. 1980; 24(1): 84-91.
- 50.Gurcan S, Karabay O, Karadenizli A, Karagol C, Kantardjiev T, Ivanov IN. Characteristics of the Turkish isolates of Francisella tularensis. Jpn J Infect Dis. 2008; 61(3): 223-5.
- 51.Helvaci S, Gedikoğlu S, Akalin H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in ten years. Eur J Epidemiol. 2000; 16(3): 271-6. [Crossref]
- 52.Celebi G, Baruönü F, Ayoğlu F,et al. Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses. Jpn J Infect Dis. 2006; 59(4): 229-34.
- 53.Kavanaugh CN. Tularemia. A consideration of one hundred and twenty-three cases, with observations at autopsy in one. Arch Intern Med. 1935; 55(1): 61-85. [Crossref]
- 54.Health Protection Agency (UK). Tularemia guidelines for action in the event of a deliberate release [İnternet]. London: HPA Centre for Infections. Version 2.4.2 [erişim 24 Ocak 2011]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_ C/1194947357555.
- 55.Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill. 2004; 9(12): E9-10.
- 56.Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol. 2007; 179(1): 532-9.
- 57.Tularaemia [İnternet]. Helsinki, Finland: Finnish Medical Society Duodecim [erişim 22 Ocak 2011]. http://www.guidelines.gov/con-tent.aspx?id=12803&search=tularemia.
| APA | KILIÇ S, YEŞİLYURT M (2011). Tularemi: Güncel tedavi seçeneklerine genel bir bakış. , 2 - 10. |
| Chicago | KILIÇ SELÇUK,YEŞİLYURT Murat Tularemi: Güncel tedavi seçeneklerine genel bir bakış. (2011): 2 - 10. |
| MLA | KILIÇ SELÇUK,YEŞİLYURT Murat Tularemi: Güncel tedavi seçeneklerine genel bir bakış. , 2011, ss.2 - 10. |
| AMA | KILIÇ S,YEŞİLYURT M Tularemi: Güncel tedavi seçeneklerine genel bir bakış. . 2011; 2 - 10. |
| Vancouver | KILIÇ S,YEŞİLYURT M Tularemi: Güncel tedavi seçeneklerine genel bir bakış. . 2011; 2 - 10. |
| IEEE | KILIÇ S,YEŞİLYURT M "Tularemi: Güncel tedavi seçeneklerine genel bir bakış." , ss.2 - 10, 2011. |
| ISNAD | KILIÇ, SELÇUK - YEŞİLYURT, Murat. "Tularemi: Güncel tedavi seçeneklerine genel bir bakış". (2011), 2-10. |
| APA | KILIÇ S, YEŞİLYURT M (2011). Tularemi: Güncel tedavi seçeneklerine genel bir bakış. Klimik Dergisi, 24(1), 2 - 10. |
| Chicago | KILIÇ SELÇUK,YEŞİLYURT Murat Tularemi: Güncel tedavi seçeneklerine genel bir bakış. Klimik Dergisi 24, no.1 (2011): 2 - 10. |
| MLA | KILIÇ SELÇUK,YEŞİLYURT Murat Tularemi: Güncel tedavi seçeneklerine genel bir bakış. Klimik Dergisi, vol.24, no.1, 2011, ss.2 - 10. |
| AMA | KILIÇ S,YEŞİLYURT M Tularemi: Güncel tedavi seçeneklerine genel bir bakış. Klimik Dergisi. 2011; 24(1): 2 - 10. |
| Vancouver | KILIÇ S,YEŞİLYURT M Tularemi: Güncel tedavi seçeneklerine genel bir bakış. Klimik Dergisi. 2011; 24(1): 2 - 10. |
| IEEE | KILIÇ S,YEŞİLYURT M "Tularemi: Güncel tedavi seçeneklerine genel bir bakış." Klimik Dergisi, 24, ss.2 - 10, 2011. |
| ISNAD | KILIÇ, SELÇUK - YEŞİLYURT, Murat. "Tularemi: Güncel tedavi seçeneklerine genel bir bakış". Klimik Dergisi 24/1 (2011), 2-10. |
